Reducing Vaccine Preventable Diseases In Children: Using National Active Hospital-based Surveillance To Evaluate And Improve Immunisation Program Performance
Funder
National Health and Medical Research Council
Funding Amount
$1,049,916.00
Summary
This proposal aims to evaluate and improve upon immunisation policy and programs for the prevention of severe childhood influenza and pertussis. Using our successful Paediatric Active Enhanced Disease Surveillance (PAEDS) network in 6 major children's hospitals across Australia, we will identify gaps in the evidence base needed to better control influenza and pertussis and in particular to ensure programs are delivered in such a way so as to address health inequalities.
EVALUATION OF THE EFFECTIVENESS OF EXPANDED NEWBORN SCREENING BY TANDEM MASS SPECTROMETRY
Funder
National Health and Medical Research Council
Funding Amount
$375,250.00
Summary
Newborn babies in Australia are routinely tested for certain treatable disorders. Testing began in the 1960's with systematic testing for phenylketonuria, a rare amino acid enzyme defect. It causes severe mental retardation which can only be prevented if treatment is begun in the first few weeks of life. By 1997, only three other disorders, congenital hypothyroidism, cystic fibrosis, and galactosaemia, had been added to the testing protocol as tests became available. Using the new technology of ....Newborn babies in Australia are routinely tested for certain treatable disorders. Testing began in the 1960's with systematic testing for phenylketonuria, a rare amino acid enzyme defect. It causes severe mental retardation which can only be prevented if treatment is begun in the first few weeks of life. By 1997, only three other disorders, congenital hypothyroidism, cystic fibrosis, and galactosaemia, had been added to the testing protocol as tests became available. Using the new technology of tandem mass spectrometry (MSMS) it is now possible to screen for up to 30 extremely rare, treatable metabolic disorders simultaneously and cheaply, but it is not clear how effective this is. A formal trial of MSMS screening, randomly assigning babies to be tested or not tested, does not seem feasible because of the rarity of the individual disorders (most with a birth prevalence much less than 1: 50,000). Huge numbers would be needed in the trial for statistical significance. We began MSMS screening in NSW April 1998 and in South Australia in February 1999. Victoria is proposing to start screening now, but there are as yet no plans for this screening in the other states. We would like to assess the effectiveness of MSMS newborn screening using the best possible evidence drawn from all data available in the whole of Australia. We plan to undertake an economic evaluation, comparing costs and benefits such as development, hospitalisations, medical complications and other outcome measures, in screened and unscreened babies and also assess harms from screening. Because only 6 specialised laboratories in Australia, in Brisbane (2), Sydney, Melbourne, Adelaide, and Perth can diagnose these disorders, we are confident that we know of all diagnosed cases of the disorders in question. We hope to be able to show whether or not there is a benefit to affected babies by implementing newborn screening tests for these rare diseases.Read moreRead less
Immunisation Practice And Policy Development In Australia: Responding To Urgent Priorities In Prevention Of Endemic And Epidemic Infectious Diseases In Children.
Funder
National Health and Medical Research Council
Funding Amount
$401,361.00
Summary
Despite high immunisation coverage rates in Australia deaths still occur in young infants from vaccine preventable diseases such as whooping cough, meningitis and influenza. My research in vaccines and immunisation involves trialing new vaccines such as meningococcal B and H1N1 vaccine to ensure their safety and effectiveness in children and investigation of new ways to deliver vaccines to improve uptake of new vaccines in the community to ensure earlier and better protection for infants and chi ....Despite high immunisation coverage rates in Australia deaths still occur in young infants from vaccine preventable diseases such as whooping cough, meningitis and influenza. My research in vaccines and immunisation involves trialing new vaccines such as meningococcal B and H1N1 vaccine to ensure their safety and effectiveness in children and investigation of new ways to deliver vaccines to improve uptake of new vaccines in the community to ensure earlier and better protection for infants and children against severe infectious diseases.Read moreRead less
Can Pentoxifylline Improve Long-term Outcomes In Preterm Infants With Late-onset Sepsis Or Necrotizing Enterocolitis – A Pragmatic, Randomized, Controlled Trial
Funder
National Health and Medical Research Council
Funding Amount
$2,901,130.00
Summary
Very preterm infants are at high risk of death and disability. Brain injury is often the result of inflammation caused by infection or bowel disease. To date, there is no treatment to reduce the harmful effects of inflammation. Pentoxifylline reduces inflammation and is a promising, safe and inexpensive treatment option for preterm infants. This study will determine whether Pentoxifylline in addition to antibiotics improves survival without disability in preterm infants.
Bio-molecular Studies For Improved Diagnosis And Management Of Australian Children With Fish Allergy
Funder
National Health and Medical Research Council
Funding Amount
$496,602.00
Summary
Allergy to fish among children is often life-long and emerging as a significant healthcare issue worldwide, while management of fish allergy is challenging due to the lack of reliable diagnostic assays. This research grant will lead to the development of novel diagnostics for fish allergy in Australia, addressing aspects of the worldwide food allergy epidemic and forms the ideal platform for the study of fish specific allergens, generating novel knowledge for greatly improved patient management.